Amyloid-Beta-Binding Peptides and Their Use for the Therapy and Diagnosis of Alzheimer's Dementia

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention relates to peptides that can specifically bind to amyloid-beta proteins. These peptides can be used for both diagnosing and treating Alzheimer's disease by either detecting the presence of amyloid-beta or interfering with its pathological role in dementia.

Use CasesContent extracted from patent full text and abstract with AI.

• Early detection of Alzheimer's disease using diagnostic tests that target amyloid-beta.
• Therapeutic intervention to treat or slow the progression of Alzheimer's by using the peptides to interfere with amyloid-beta aggregation.
• Imaging applications in neurology to visualize amyloid-beta deposits in the brain.
• Monitoring the effectiveness of Alzheimer's treatments by tracking amyloid-beta levels.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a targeted approach to Alzheimer's disease diagnosis and therapy.
• May enable earlier and more accurate detection of Alzheimer's, potentially before symptoms develop.
• Could help slow or halt disease progression by interfering with amyloid-beta pathology.
• Non-invasive testing options may be possible using the peptides for biomarkers or imaging.
• Potential to improve patient outcomes and reduce healthcare costs by enabling timely intervention.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to amyloid-beta-binding peptides and their use for the therapy and diagnosis of Alzheimer's dementia.